DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Lung Giant Cell Carcinoma — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLung Giant Cell Carcinoma maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Structures already discussed alongside lung giant cell carcinoma in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Crystal structure of EGFR kinase — Afatinib has a real, experimentally solved structure in complex with this target (PDB 4G5J, 2.8 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet 0wmdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4G5J · 2.8 Å · ligand Afatinib (0WM). Experimental structure, not a prediction.
What the evidence adds up to
Giant-cell carcinoma of the lung is usually rapidly fatal, and nearly all published cases up to 1969 were described from postmortem findings. In that year, three surgical specimens from resected giant-cell carcinomas were described, and the patients’ subsequent courses summarised; a further nine surgically treated cases were found in the literature. The tumour was thought to be an anaplastic variant of adenocarcinoma, and its aggressive behaviour a reflection of its degree of anaplasia. Despite that behaviour, patients could survive for many years if the tumour was resected.
A 2022 study examined real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. The supplemental material for that study is available but the abstract itself does not report any numerical results, response rates, or survival data. No drug names, treatment regimens, or efficacy comparisons are given in the abstract.
A 2015 review focused on maintenance therapy for small cell lung cancer, not giant cell carcinoma. It noted that small cell lung cancer is highly sensitive to first-line chemotherapy but most patients relapse quickly after first-line therapy, and that despite many clinical trials of chemotherapy, biological agents, and molecular targeting agents since the 1980s, there remains a substantial lack of consensus on appropriate maintenance therapy. This review does not address giant cell carcinoma.
What is still missing is any prospective trial specifically for advanced giant cell carcinoma of the lung, any data on modern systemic therapy outcomes in that histology, and any patient stratification beyond surgical resectability. The 2022 study’s full results may address some of these gaps, but the abstract alone does not.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Pathology · 1969 · 9 citations · open access
Pathology and survival in operable cases of giant-cell carcinoma of the lung
AbstractGiant-cell carcinoma of the lung is usually rapidly fatal and nearly all of the published cases have been described on the basis of postmortem findings. The surgical specimens from three resected giant-cell carcinomas are described and the subsequent courses of the patients are summarized. A further nine surgically treated cases have been found in the literature. Giant-cell carcinoma of the lung is thought to be an anaplastic variant of adenocarcinoma and its aggressive behaviour is a reflection of its degree of anaplasia. Despite the aggressive behaviour of this type of cancer, patients may survive for many years if the tumour is resected.
[Research Progression of Maintenance Therapy in Small Cell Lung Cancer].
AbstractLung cancer is one of the common malignant tumors in the world, the incidence of small cell lung cancer is about 15% among them. Small cell lung cancer is highly sensitive to first-line chemotherapy, but most of the patients relapse after the first-line therapy quickly. Despitemany clinical researchof chemotherapy, biological agents and molecular targeting agents since the 1980s, there still remains a substantial lack of consensus regarding the appropriate therapeutic management on maintenance therapy of small cell lung cancer. The review focuses on maintenance therapy of small cell lung cancer.
Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: a database of 693 cases
AbstractThis Publication Perspective provides a summary of the article ‘Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Database of 693 Cases’ by James Chih-Hsin Yang and co-authors. The paper, originally published in the Journal of Thoracic Oncology, comprehensively analysed the effect of afatinib treatment in 693 patients with non-small cell lung cancer harboring uncommon EGFR mutations. The results provide important information when considering optimal treatment for tumors with uncommon EGFR mutations, including compound mutations.
Sage Journals Data · 2022 · 0 citations · open access
sj-docx-1-tam-10.1177_17588359221133889 – Supplemental material for Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma
AbstractSupplemental material, sj-docx-1-tam-10.1177_17588359221133889 for Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma by Chia-Ling Chang, Min-Shu Hsieh, Jin-Yuan Shih, Yi-Hsuan Lee, Wei-Yu Liao, Chia-Lin Hsu, Ching-Yao Yang, Kuan-Yu Chen, Jih-Hsiang Lee, Chao-Chi Ho, Tzu-Hsiu Tsai, James Chih-Hsin Yang and Chong-Jen Yu in Therapeutic Advances in Medical Oncology
INDIGO (University of Illinois at Chicago) · 2022 · 0 citations · open access
sj-docx-1-tam-10.1177_17588359221133889 – Supplemental material for Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma
AbstractSupplemental material, sj-docx-1-tam-10.1177_17588359221133889 for Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma by Chia-Ling Chang, Min-Shu Hsieh, Jin-Yuan Shih, Yi-Hsuan Lee, Wei-Yu Liao, Chia-Lin Hsu, Ching-Yao Yang, Kuan-Yu Chen, Jih-Hsiang Lee, Chao-Chi Ho, Tzu-Hsiu Tsai, James Chih-Hsin Yang and Chong-Jen Yu in Therapeutic Advances in Medical Oncology
Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study
AbstractThis partially randomized phase I/II trial studies the side effects and best dose of sunitinib malate and to see how well it works when given together with cisplatin or carboplatin and etoposide in treating patients with extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether cisplatin or carboplatin and etoposide are more effective when given with or without sunitinib malate in treating small cell lung cancer.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
